uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2015-22-1-38-42uzspbgmu-109Research ArticleОРИГИНАЛЬНЫЕ РАБОТЫORIGINAL PAPERSРОЛЬ ФАКТОРА РОСТА ФИБРОБЛАСТОВ 23-го ТИПА В РАЗВИТИИ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ И НАРУШЕНИЙ КАЛЬЦИЙ-ФОСФОРНОГО ОБМЕНА У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕКRole of the fibroblast growth factor type 23 in progression of complications and imbalance of calcium-phosphoric metabolism with patients suffering chronic kidney diseaseЕсаянА. М.YesayanA. M.noemail@neicon.ruНимгироваА. Н.NimgirovaA. N.noemail@neicon.ruКаюковИ. Г.KayukovI. G.noemail@neicon.ruЯковенкоА. А.YakovenkoA. A.noemail@neicon.ruПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. ПавловаРоссия2015300320152213842Copyright © Есаян А.М., Нимгирова А.Н., Каюков И.Г., Яковенко А.А., 20152015Есаян А.М., Нимгирова А.Н., Каюков И.Г., Яковенко А.А.Yesayan A.M., Nimgirova A.N., Kayukov I.G., Yakovenko A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/109

В обзоре рассмотрена роль фактора роста фибробластов 23-го типа (ФРФ 23) в прогрессировании почечной дисфункции, а также его кардиоваскулярные эффекты и влияние на кальций-фосфорный обмен у пациентов с хронической болезнью почек. Рассматриваются различия эффектов ФРФ 23 на додиализной стадии хронической болезни почек, у диализных пациентов и у реципиентов почечного аллотрансплантата.

The review discusses the role of fibroblast growth factor type 23 (FGF-23) in progression of renal dysfunction and its cardiovascular effects, calcium-phosphorus metabolism in patients with chronic kidney disease. Differences in the FGF-23 effects at predialysis stage of chronic kidney disease, in dialysis patients and renal allograft recipients are analyzed.

хроническая болезнь почекфактор роста фибробластов 23-го типатрансплантация почкиchronic kidney diseasefibroblast growth factor type 23kidney transplantationReferencesСмирнов А. В., Каюков И. Г., Добронравов В. А. Концепция факторов риска в нефрологии: вопросы профилактики и лечения хронической болезни почек // Нефрология. - 2008. - № 12 (1). - С. 7-13.Смирнов А. В., Каюков И. Г., Добронравов В. А. Концепция факторов риска в нефрологии: вопросы профилактики и лечения хронической болезни почек // Нефрология. - 2008. - № 12 (1). - С. 7-13.Bacchetta J., Dubourg L., Harambat J. et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease // J. Clin. Endocrinol. Metab. - 2010. - № 95. - Р. 1741-1748.Bacchetta J., Dubourg L., Harambat J. et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease // J. Clin. Endocrinol. Metab. - 2010. - № 95. - Р. 1741-1748.Bhan I., Shah A., Holmes J. et al. Post-transplant hypophosphatemia: Tertiary Hyper-Phosphatoninism? // Kidney Int. - 2006. - № 70. - Р. 1486-1494.Bhan I., Shah A., Holmes J. et al. Post-transplant hypophosphatemia: Tertiary Hyper-Phosphatoninism? // Kidney Int. - 2006. - № 70. - Р. 1486-1494.Cai Q., Hodgson S. F., Kao P. C. et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia // N. Engl. J. Med. - 1994. -№ 330. - Р. 1645-1649.Cai Q., Hodgson S. F., Kao P. C. et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia // N. Engl. J. Med. - 1994. -№ 330. - Р. 1645-1649.Evenepoel P., Meijers B. K., de Jonge H. et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation // Clin. J. Am. Soc. Nephrol. - 2008. - № 3. - Р. 1829-1836.Evenepoel P., Meijers B. K., de Jonge H. et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation // Clin. J. Am. Soc. Nephrol. - 2008. - № 3. - Р. 1829-1836.Evenepoel P., Naesens M., Claes K. et al. Tertiary ‘hyper-phosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients // Am. J. Transplant. - 2007. - № 7. - Р. 1193-1200.Evenepoel P., Naesens M., Claes K. et al. Tertiary ‘hyper-phosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients // Am. J. Transplant. - 2007. - № 7. - Р. 1193-1200.Fliser D., Kollerits B., Neyer U. et al. Fibroblast Growth Factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study // J. of the Am. Society of Nephrology. - 2007. - № 18 (9). -Р. 2600-2608.Fliser D., Kollerits B., Neyer U. et al. Fibroblast Growth Factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study // J. of the Am. Society of Nephrology. - 2007. - № 18 (9). -Р. 2600-2608.Gattineni J., Bates C., Twombley K. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 // Am. J. of Physiology: Renal Physiology. - 2009. - № 297 (2). -Р. 282-291.Gattineni J., Bates C., Twombley K. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 // Am. J. of Physiology: Renal Physiology. - 2009. - № 297 (2). -Р. 282-291.Green J., Debby H., Lederer E. et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia // Kidney Int. - 2001. -№ 60. - Р. 1182-1196.Green J., Debby H., Lederer E. et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia // Kidney Int. - 2001. -№ 60. - Р. 1182-1196.Gutierrez O. M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis // The New England J. of Medicine. - 2008. -№ 359 (6). - Р. 584-592.Gutierrez O. M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis // The New England J. of Medicine. - 2008. -№ 359 (6). - Р. 584-592.Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease // J. Am. Soc. Nephrol. - 2005. - № 16. - Р. 2205 - 2215Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease // J. Am. Soc. Nephrol. - 2005. - № 16. - Р. 2205 - 2215Hansen D., Rasmussen K., Pedersen S. M. et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol // Nephrology Dialysis Transplantation. - 2012. - № 27 (6). - Р. 2263 - 2269.Hansen D., Rasmussen K., Pedersen S. M. et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol // Nephrology Dialysis Transplantation. - 2012. - № 27 (6). - Р. 2263 - 2269.Howard R. J., Patton P. R., Reed A. I. et al. The changing causes of graft loss and death after kidney transplantation // Transplantation - 2002. - № 73. - Р. 1923-1928.Howard R. J., Patton P. R., Reed A. I. et al. The changing causes of graft loss and death after kidney transplantation // Transplantation - 2002. - № 73. - Р. 1923-1928.Hsu H. J., Wu M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients // Am. J. Med. Sci. - 2009. - № 337. - Р. 116-122.Hsu H. J., Wu M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients // Am. J. Med. Sci. - 2009. - № 337. - Р. 116-122.Isakova T., Xie H., Yang W. et al. Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease // JAMA. - 2011. - № 305 (23). - Р. 2432 - 2439.Isakova T., Xie H., Yang W. et al. Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease // JAMA. - 2011. - № 305 (23). - Р. 2432 - 2439.Jean G., Bresson E., Terrat J. C. et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences // Nephrology Dialysis Transplantation. - 2009. - № 24 (3). - Р. 948 - 955.Jean G., Bresson E., Terrat J. C. et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences // Nephrology Dialysis Transplantation. - 2009. - № 24 (3). - Р. 948 - 955.Jean G., Terrat J. C., Vanel T. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrology Dialysis Transplantation. - 2009. - № 24 (9). - Р. 2792 - 2796.Jean G., Terrat J. C., Vanel T. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrology Dialysis Transplantation. - 2009. - № 24 (9). - Р. 2792 - 2796.Katoh Y., Katoh M. Comparative genomics on mammalian FGF6-FGF23 locus // Int. J. of Molecular Medicine. - 2005. - № 16 (2). - Р. 355 - 358.Katoh Y., Katoh M. Comparative genomics on mammalian FGF6-FGF23 locus // Int. J. of Molecular Medicine. - 2005. - № 16 (2). - Р. 355 - 358.Kurosu H., Ogawa Y., Miyoshi. M. et al. Regulation of fibroblast growth factor-23 signaling by Klotho // J. Biol. Chem. - 2006. - № 281. - Р. 6120 - 6123.Kurosu H., Ogawa Y., Miyoshi. M. et al. Regulation of fibroblast growth factor-23 signaling by Klotho // J. Biol. Chem. - 2006. - № 281. - Р. 6120 - 6123.Levi M. Post-transplant hypophosphatemia // Kidney Int. - 2001. - № 59. - Р. 2377 - 2387.Levi M. Post-transplant hypophosphatemia // Kidney Int. - 2001. - № 59. - Р. 2377 - 2387.Middleton R. J., Parfrey P. S., Foley R. N. Left ventricular hypertrophy in the renal patient // J. Am. Soc. Nephrol. - 2001. - № 12. - Р. 1079- 1084.Middleton R. J., Parfrey P. S., Foley R. N. Left ventricular hypertrophy in the renal patient // J. Am. Soc. Nephrol. - 2001. - № 12. - Р. 1079- 1084.Mirza M. A. I., Hansen T., Johansson L. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community // Nephrology Dialysis Transplantation. - 2009. - № 24 (10). - Р. 3125 - 3131.Mirza M. A. I., Hansen T., Johansson L. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community // Nephrology Dialysis Transplantation. - 2009. - № 24 (10). - Р. 3125 - 3131.Ninkovic M., Skingle S. J., Bearcroft P. W. et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation // Eur. J. Gastroenterol. Hepatol. - 2000. - № 12. - Р. 931-935.Ninkovic M., Skingle S. J., Bearcroft P. W. et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation // Eur. J. Gastroenterol. Hepatol. - 2000. - № 12. - Р. 931-935.Norris K. C., Greene T., Kopple J. et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease // J. Am. Soc. Nephrol. - 2006. - № 17 (10). - Р. 2928 - 2936.Norris K. C., Greene T., Kopple J. et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease // J. Am. Soc. Nephrol. - 2006. - № 17 (10). - Р. 2928 - 2936.Oliveira R. B., Cancela A. L., Graciolli F. G. et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? // Clin. J. Am. Soc. Nephrol. - 2010. - № 5. - Р. 286 - 291.Oliveira R. B., Cancela A. L., Graciolli F. G. et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? // Clin. J. Am. Soc. Nephrol. - 2010. - № 5. - Р. 286 - 291.Riminucci M. et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting // J. of Clinical Investigation. - 2003. - № 112. - Р. 683 - 692.Riminucci M. et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting // J. of Clinical Investigation. - 2003. - № 112. - Р. 683 - 692.Saji F., Shiizaki K., Shimada S. et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron // Physiology. - 2009. - № 111 (4). - Р. 59 - 66.Saji F., Shiizaki K., Shimada S. et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron // Physiology. - 2009. - № 111 (4). - Р. 59 - 66.Sitara D., Razzaque M. S., Hesse M. et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophos phatemia in Phex-deficient mice // Matrix Biol. - 2004. - № 23. - Р. 421-432.Sitara D., Razzaque M. S., Hesse M. et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophos phatemia in Phex-deficient mice // Matrix Biol. - 2004. - № 23. - Р. 421-432.The ADHR Consortium. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23 // Nature Genetics. - 2000. - № 26. - Р. 345 - 348.The ADHR Consortium. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23 // Nature Genetics. - 2000. - № 26. - Р. 345 - 348.Wesseling-Perry K., Pereira R. C., Sahney S. et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism // Kidney Int. - 2011. - № 79 (1). - Р. 112-119.Wesseling-Perry K., Pereira R. C., Sahney S. et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism // Kidney Int. - 2011. - № 79 (1). - Р. 112-119.Wolf M., Molnar M., Amaral A. et al. Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality // J. Am. Soc. Nephrol. - 2011. - № 22. - Р. 956 - 966.Wolf M., Molnar M., Amaral A. et al. Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality // J. Am. Soc. Nephrol. - 2011. - № 22. - Р. 956 - 966.Yamashita T. et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain // Biochemical Biophysical Research Communications. - 2000. - № 277 (2). - Р. 494 - 498.Yamashita T. et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain // Biochemical Biophysical Research Communications. - 2000. - № 277 (2). - Р. 494 - 498.Yan X., Yokote H., Jing X. et al. Fibroblast growth factor 23 reduces expression of type IIa Na + /Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells // Genes to Cells. - 2005. - № 10 (5). - Р. 489 - 502.Yan X., Yokote H., Jing X. et al. Fibroblast growth factor 23 reduces expression of type IIa Na + /Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells // Genes to Cells. - 2005. - № 10 (5). - Р. 489 - 502.

The authors declare that there are no conflicts of interest present.